UNAIDS, WHO & the global HIV response — the road to 2030 runs through a funding crisis.

Two United Nations-linked bodies sit at the center of the global HIV response, and most people living with HIV have never heard either name spoken in a clinic. The Joint United Nations Programme on HIV/AIDS (UNAIDS) coordinates political commitment, tracks the epidemiology, and publishes the numbers every country measures itself against. The World Health Organization (WHO) writes the clinical guidance — who should get pre-exposure prophylaxis (PrEP), which antiretroviral regimen is first-line, how testing should work — that ministries of health, PEPFAR, and the Global Fund translate into actual services.

Neither body treats a single patient. Both shape whether treatment and prevention exist where a person living with HIV happens to live. In 2026, both are under more strain than at any point since the response scaled up in the mid-2000s — not because the science stalled, but because the money did.

Two bodies, one mission — and both are strained

UNAIDS was created in 1996 by merging the HIV-related work of multiple UN agencies into a single joint program, explicitly because the epidemic did not respect the boundaries between health, development, human rights, and humanitarian response.1 It does not run clinics or manufacture drugs. Its job is to hold the political center: publishing the Global AIDS Update every year, setting global targets through the Global AIDS Strategy, convening the UN General Assembly's high-level meetings on AIDS, and pushing governments toward policies — decriminalization, harm reduction, gender-based violence response — that the epidemiology says matter.

WHO's role is narrower and more technical: it is the normative body that turns clinical trial evidence into consolidated guidelines member states can adopt directly. When WHO recommends dolutegravir-based treatment, or twice-yearly injectable PrEP, or a specific HIV testing algorithm, that recommendation becomes the default architecture for national HIV programs across dozens of low- and middle-income countries that lack the capacity to run their own independent guideline-development process.3

The two organizations are meant to work in sequence: WHO tells the world what the evidence supports; UNAIDS tells the world how far implementation has gotten and applies pressure where it has stalled. That division of labor has functioned for two decades. It is still functioning in 2026 — WHO issued new lenacapavir PrEP guidelines in July 2025, and UNAIDS published its Global AIDS Update on schedule2 — but both organizations are now doing that work against a backdrop UNAIDS itself describes as a "historic funding crisis" threatening to unravel decades of progress.2 WHO's own Director-General, Tedros Adhanom Ghebreyesus, put it starkly at the 2026 International AIDS Conference: new HIV acquisitions and AIDS-related deaths are at their lowest levels in three decades, "but that progress is fragile."4

This piece treats them as one framing because that is how they function for a person living with HIV anywhere in the world: WHO decides what "standard of care" means; UNAIDS decides whether your country is getting close to delivering it, and says so publicly when it is not.

The numbers, as of the latest data

UNAIDS's July 2025 Global AIDS Update, titled AIDS, Crisis and the Power to Transform, and the fact sheet UNAIDS maintains alongside it, report that at the end of 2025, 41.0 million people were living with HIV globally, with a plausible range of 35.3 million to 47.5 million given how estimates are modeled.2 Of those, 39.7 million were adults and 1.3 million were children under 15. Women and girls made up 53% of everyone living with HIV worldwide.2

In 2025, an estimated 1.2 million people newly acquired HIV — down 65% from the epidemic's 1994 peak of roughly 3.5 million, and down 42% since 2010.2 An estimated 570,000 people died of AIDS-related illness that year, a 73% decline from the 2004 peak.2 Still: someone died of HIV-related causes roughly every minute of 2025.2 Progress has been real and progress has also stalled — new acquisitions fell fastest among children over the past decade, but that decline has flattened in recent years, which UNAIDS ties directly to prevention-program disruption.2

By the end of December 2025, 32.1 million people were accessing antiretroviral therapy, up from 7.6 million in 2010 — a scale-up that remains one of the most consequential public-health achievements of this century.2 That is 78% of everyone living with HIV. It leaves roughly 9 million people known to be living with HIV who are not yet on treatment, plus an estimated 5 million people living with HIV who do not know their status at all.2

Where the gaps concentrate

The global averages hide sharp disparities by age, sex, and population. Treatment coverage for children (0–14) sits at 55%, far below the 79% coverage among adults.2 Coverage is also uneven by sex: 84% of women living with HIV were on treatment in 2025, versus 74% of men.2 UNAIDS's key-populations analysis found gay men and other men who have sex with men face 18 times the risk of HIV acquisition compared with the general adult population; people who inject drugs face 34 times the risk; sex workers and transgender women each face roughly 17 times the risk; and people in prisons and other closed settings have twice the HIV prevalence of the general population.2 Those ratios are not biological facts about who HIV "targets" — they are the measurable output of criminalization, stigma, and structural exclusion from health systems, which is exactly why WHO frames its guidance around key populations rather than "risk groups."

95-95-95 — what the targets mean, and who is hitting them

The 90-90-90 targets, adopted in 2014, asked that by 2020, 90% of people living with HIV know their status, 90% of those diagnosed be on treatment, and 90% of those on treatment be virally suppressed. The world did not reach them on schedule, so in 2020 UNAIDS raised the bar rather than lower it: 95-95-95 by 2025, an interim checkpoint on the way to ending AIDS as a public health threat by 2030.1

The distinction matters practically, not just numerically. Multiplying 95% by 95% by 95% yields roughly 86% of all people living with HIV virally suppressed — a population-level target public-health programs can actually plan against, distinct from "everyone" and distinct from "cure."

Against that yardstick, the 2025 global cascade is: 88% of people living with HIV know their status; of those, 89% are on treatment; of those, 95% are virally suppressed.2 Multiplied through, roughly 74% of all people living with HIV worldwide are virally suppressed — real progress from a decade ago, and still short of the 86% population target.2 The gap is concentrated in the first two 95s — status awareness and treatment linkage — not in the third: once someone starts treatment and stays on it, viral suppression rates are consistently strong across nearly every demographic UNAIDS tracks.2

Some countries got there years early. UNAIDS and independent analyses in The Lancet HIV confirm that Botswana reached 95-95-95 in 2021 — four years ahead of the global deadline, and a striking result in a country where roughly one in five adults lives with HIV.6 Eswatini, Rwanda, the United Republic of Tanzania, and Zimbabwe followed, and UNAIDS names those five as the first countries to hit all three targets, with 16 more — eight of them in sub-Saharan Africa — close behind.7 Switzerland and several other high-income countries are also cited among early achievers on viral suppression specifically.7

The question is no longer whether we can end AIDS, the question is whether we choose to end AIDS. When prevention disappears, infections rise. When treatment is interrupted, people die. — Winnie Byanyima, UNAIDS Executive Director, press conference at AIDS 2026, Rio de Janeiro, July 2026.4

The countries falling behind are not a random scatter — they cluster where key-population criminalization is strictest, where health systems are weakest, or where donor dependence is highest and now most exposed to the funding pullback. "Epidemic control," the shorthand UNAIDS and PEPFAR use for reaching 95-95-95 at a population level, is a public-health threshold, not an endpoint. It does not mean HIV disappears from a country. It means new transmission slows enough that the epidemic stops growing faster than the response can manage it — a meaningfully different, and more honest, goal than "eradication," which no one credible is promising by 2030.

WHO's Consolidated Guidelines — the backbone under every national HIV program

Since 2016, WHO has published its HIV recommendations as a single, continuously updated document: the Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring. The 2021 edition brought together everything WHO had issued since 2016 into one reference, including new chapters on advanced HIV disease and management of common comorbidities like cryptococcal disease and tuberculosis.3 Rather than issuing a wholesale new edition every few years, WHO now updates individual chapters and modules as evidence changes: a 2024 HIV testing update, a 2024 post-exposure prophylaxis update, a September 2025 service-delivery update on integrating hypertension, diabetes, and mental health care into HIV programs, and a December 2025 update to HIV clinical management recommendations covering new antiretroviral options and shorter tuberculosis prevention regimens.3

TLD as the global default

The clearest example of how a WHO recommendation reshapes care at scale is the shift to TLD — the fixed-dose combination of tenofovir, lamivudine, and dolutegravir — as the preferred first-line antiretroviral regimen for most adults and adolescents starting treatment.8 Dolutegravir-based regimens have a higher genetic barrier to resistance, fewer side effects than older options, and once-daily dosing, and WHO's push to transition national programs to TLD is one of the largest coordinated regimen switches in the history of the HIV response — millions of people worldwide moved from older, more toxic regimens to TLD over the past several years, and WHO continues to track and support that transition where it remains incomplete.8

The practical significance for a person living with HIV is this: the pill someone takes in Lilongwe or Lima or rural Florida is, increasingly, the same pill — decided not by whichever pharmaceutical company markets hardest in that country, but by a WHO technical review of the trial evidence. That standardization is also why disruptions to the global supply chain, or to programs that pay for TLD in donor-dependent countries, ripple so widely.

Key populations — why the language and the framework both matter

WHO's July 2022 guidance, formally titled Consolidated Guidelines on HIV, Viral Hepatitis and STI Prevention, Diagnosis, Treatment and Care for Key Populations, names five groups: gay men and other men who have sex with men, trans and gender-diverse people, sex workers, people who inject drugs, and people in prisons and other closed settings.9 The guidance is explicit that what elevates HIV risk for these groups is not identity or behavior in isolation — it is the compounding effect of criminalization, stigma, and structural exclusion that obstructs access to prevention, testing, and treatment.9

"Key populations" replaced older language — "high-risk groups," "vulnerable populations" used loosely — for a specific evidence-based reason: the earlier framing implied risk was an intrinsic property of the person or their behavior, which both mischaracterized the epidemiology and reinforced the stigma that keeps people out of care. The key-populations framework instead names the structural conditions — a sodomy law, a sex-work criminalization statute, a prison system without harm reduction — as the thing driving disparate risk, and asks health systems to design services around removing those barriers rather than moralizing about the people affected by them.9 WHO's guidance calls specifically for services that key-population communities help design and, wherever possible, help lead.9

This is also where the funding cuts have landed hardest and fastest. A KFF analysis of nearly 170 PEPFAR-funded organizations across 46 countries found that services aimed specifically at key populations — alongside PrEP, condom distribution, and prevention of mother-to-child transmission — were disproportionately stopped, interrupted, or disrupted after the 2025 U.S. funding freeze, with more than 1,700 HIV service sites closing entirely.10 Community-based programs, which is where most key-population-specific services in donor-dependent countries were delivered, were hit harder than large international implementers.10

PEPFAR and the Global Fund — the money behind the guidelines

Guidelines only matter if someone pays for the drugs, tests, and staff to deliver them. Two mechanisms have carried most of that weight for two decades. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), launched in 2003 under President George W. Bush, is credited with saving more than 26 million lives.10 The Global Fund to Fight AIDS, Tuberculosis and Malaria, created in 2002 as a multilateral financing partnership, pools contributions from governments, foundations, and the private sector and channels them to country-led programs across all three diseases.

PEPFAR's 2025–2026 crisis, in sequence

PEPFAR has been reauthorized by Congress four times, most recently in March 2024 for one year; that authorization expired on March 25, 2025.10 Because PEPFAR is a permanent part of U.S. law, expiration of the time-limited authorization did not by itself end the program — but a separate, more disruptive sequence of executive actions did enormous damage in parallel. On January 20, 2025, the incoming administration issued an executive order requiring a 90-day review of foreign aid; a subsequent stop-work order froze essentially all PEPFAR programming, including ongoing distribution of antiretroviral therapy.10 A limited waiver on February 1–6, 2025 allowed treatment, testing, and prevention of mother-to-child transmission to resume, but explicitly excluded PrEP for anyone other than pregnant and breastfeeding women — cutting off ongoing PrEP users and new prevention enrollment for everyone else, including gay men, sex workers, and other key populations.10

The U.S. Agency for International Development, which had obligated roughly 60% of PEPFAR's bilateral assistance, was dissolved; its remaining global-health functions moved to a new State Department bureau over the course of 2025.10 KFF identified 379 global-health awards with HIV activities among canceled foreign-assistance funding; 71% of those were terminated outright.10 A tracking survey found PrEP initiations fell between 13% and 66% across five high-burden countries comparing January–September 2025 with the same months in 2024.10 By 2026, the administration confirmed plans for a phased drawdown of PEPFAR programming in South Africa, with most programs ending by September 30, 2026, and additional reporting indicated the administration intends to cease PEPFAR funding entirely by early 2027.10

Congress, notably, did not go along with the scale of cuts the administration proposed: it appropriated $4.8 billion for PEPFAR and $1.25 billion for the Global Fund in FY 2026 — close to prior-year levels, despite White House budget requests for far less.10 That gap between congressional appropriation and what has actually been obligated, disbursed, and reached implementers on the ground is itself part of the crisis: NPR reported the State Department had only spent about 70% of available PEPFAR funds after Congress restored funding levels.4

The Global Fund's parallel squeeze

The Global Fund's Eighth Replenishment, meant to fund its 2026–2028 cycle, sought $18 billion. Pledges from its November 2025 summit in Johannesburg reached $11.34 billion, and the final tally after continued mobilization through early 2026 landed at $12.64 billion — a real sum, and roughly $5.4 billion short of the target the Global Fund said was needed to sustain progress against HIV, TB, and malaria.12 The United States pledged $4.6 billion to that replenishment, a notable show of continuity given the same administration's parallel dismantling of PEPFAR — but it fell short of the $6 billion the prior administration pledged to the Seventh Replenishment, of which only about $3.12 billion had actually been paid despite congressional appropriation.4

IAS President Beatriz Grinsztejn summarized the moment bluntly at AIDS 2026: "Never has donor funding fallen so far, so fast, and those most vulnerable are already paying the price. Donor countries are choosing to walk away while many high-burden countries remain shackled by debt they cannot escape."13

Lenacapavir — the science moved faster than access

If there is one place the 2026 story is not only bad news, it is prevention science. Lenacapavir is a long-acting HIV-1 capsid inhibitor, delivered as a subcutaneous injection every six months, that produced two of the most striking PrEP trial results ever published. In the PURPOSE-1 trial, presented in 2024, cisgender women receiving twice-yearly lenacapavir had zero new HIV infections among more than 2,100 participants.14 PURPOSE-2, in cisgender men, transgender men, transgender women, and gender-nonbinary people who have sex with partners assigned male at birth, found a 96% reduction in HIV acquisition risk compared with daily oral PrEP — only two infections among 2,180 participants receiving lenacapavir, versus nine among 1,087 people on daily oral tenofovir disoproxil fumarate/emtricitabine.14

The FDA approved injectable lenacapavir for PrEP in June 2025, and WHO followed in July 2025 with new guidelines recommending it as an additional prevention option — a strong recommendation, based on moderate-to-high certainty evidence — alongside a companion recommendation supporting rapid diagnostic tests for people starting or continuing any long-acting injectable PrEP.15 WHO's Dr. Meg Doherty, director of the department overseeing global HIV programs, called it practical for real-world use: "Dosing every six months with LEN could be particularly appealing for individuals who prefer fewer visits to the clinic or face difficulties with daily oral PrEP. It has the potential to enhance adherence and extend its reach to those in need of HIV prevention."15

Gilead, lenacapavir's manufacturer, signed royalty-free voluntary licensing agreements in October 2024 with six generic manufacturers to produce and sell low-cost versions across 120 primarily low- and lower-middle-income countries, and committed to supplying its own product at no profit until generic supply catches up with demand.16 That licensing move is genuinely unusual for a first-in-class drug this soon after approval, and it reflects lessons learned from the delayed rollout of earlier PrEP technologies.

The gap is that voluntary licenses do not manufacture product instantly, and the funding collapse hit at precisely the moment countries needed to build procurement and delivery systems for a brand-new prevention tool. IAS President Beatriz Grinsztejn named this directly at AIDS 2026: "We have great innovation, we have prevention technologies that the HIV community has dreamed about for years — unfortunately, at the same time, we do not have the funding necessary to deliver these technologies to the people who need them most."13 In September 2025 the U.S. announced a partnership between PEPFAR and the Global Fund to deliver long-acting injectable PrEP to up to 2 million people in high-burden countries by 2028 — a real commitment, running alongside the same administration's broader PEPFAR drawdown.10

U=U, globally — a message that travels further than a viral-load test does

Undetectable equals untransmittable — U=U — is the finding, confirmed across multiple large studies including the PARTNER studies, that a person living with HIV on effective treatment with a sustained undetectable viral load cannot sexually transmit the virus to a partner. The Prevention Access Campaign built the consensus statement and the global U=U movement around that evidence starting in 2016, and WHO has incorporated the underlying science into its own guidance in the years since.17 By the campaign's own tracking, U=U has been formally endorsed by more than 1,000 organizations across over 100 countries.17

The gap between that message and its global reach is a monitoring problem as much as a messaging one. U=U is only meaningful for someone who knows their viral load, and routine viral-load monitoring — the blood test that confirms suppression, not just that someone is taking pills — remains far less consistently available in lower-income settings than in the U.S. or Western Europe. UNAIDS's own cascade data show suppression rates lag behind testing and treatment coverage in exactly the settings where laboratory infrastructure is thinnest.2 A person can be adherent, undetectable, and unable to prove it — which matters clinically, for disclosure conversations, and for the stigma reduction U=U is designed to enable.

Women and girls — a gendered epidemic, and where DREAMS fits

HIV has never distributed evenly by sex, and UNAIDS's 2025 data confirms the pattern persists: women and girls are 53% of everyone living with HIV worldwide and accounted for 44% of new acquisitions in 2025.2 The concentration is sharpest among adolescent girls and young women in Eastern and Southern Africa, where UNAIDS and PEPFAR have long documented dramatically higher incidence than among their male peers of the same age — driven by age-disparate relationships, gender-based violence, economic dependency, and school dropout, not by any biological difference in susceptibility.

PEPFAR's DREAMS partnership — Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe — launched in 2014 with private-sector partners including the Bill & Melinda Gates Foundation, Gilead, Johnson & Johnson, and ViiV Healthcare, specifically to address those structural drivers rather than treat HIV risk in adolescent girls as an individual behavior problem.18 The model layers interventions — HIV prevention services, gender-based-violence response, secondary-school support, economic strengthening — because the evidence showed no single service moved the needle alone. DREAMS drove reductions in new HIV diagnoses among adolescent girls and young women of 25% or more across nearly all of its geographic footprint in its earlier years.18

DREAMS is also one of the programs KFF specifically found scaled back amid the 2025 funding disruption, with declining support recorded through FY 2025 Q4 and continuing negative effects on programs for adolescent girls and young women reported as of December 2025.10 A program built on the recognition that gender-based violence and HIV cannot be addressed separately is now itself a casualty of the same funding contraction affecting every other prevention line item.

The advocacy space — what pressure at the UN and WHO level actually does

Neither UNAIDS's targets nor WHO's guidelines write themselves, and neither gets adopted by governments automatically. A network of advocacy and community organizations does the work of translating evidence into political pressure and holding both bodies, and the donor governments behind them, accountable. AVAC has spent decades building the evidence-to-advocacy pipeline for HIV prevention research specifically, including sustained work with key-population communities and organizations to make sure new prevention tools like lenacapavir reach the populations the trials were designed to serve.19 The International AIDS Society (IAS) convenes the biennial International AIDS Conference — AIDS 2026 drew HIV researchers, clinicians, and advocates to Rio de Janeiro, Brazil, in July 2026 — and its president has become one of the most visible public voices naming the funding crisis for what it is.13

Community and women-led organizations occupy a different, equally necessary lane: groups built and led by people living with HIV, including networks organized specifically around women living with HIV, push UNAIDS and WHO to keep lived experience inside guideline development rather than treating affected communities purely as guidance recipients. That is consistent with both organizations' own stated commitments to "nothing about us without us" — a principle easier to state than to operationalize when guideline committees, donor boards, and country programs all still skew toward technical experts over people actually living with HIV.

What this advocacy layer demonstrably achieves: it kept PEPFAR's 2025 stop-work order in the news cycle and in federal court simultaneously, contributing to the preliminary injunction that forced partial repayment for halted work.10 It kept lenacapavir access, not just lenacapavir efficacy, on the agenda at IAS 2025 and AIDS 2026, forcing Gilead's licensing terms and the funding gap into the same conversation rather than letting a trial result stand in for actual delivery.13 And it is the reason "key populations" language survived in WHO guidance through a period when the term itself became politically contested in some donor-country politics.

What you can do

None of this is abstract for a person living with HIV whose local clinic depends, even indirectly, on PEPFAR or Global Fund financing — and even for people in well-resourced health systems, the global response's stability affects drug pricing, research investment, and the political climate around HIV everywhere.

AIDS 2026, the 26th International AIDS Conference, was held in Rio de Janeiro, Brazil, in July 2026, under the theme "Rethink. Rebuild. Rise." — a framing IAS chose deliberately for a moment defined as much by funding collapse as by scientific breakthrough.13 The next major global checkpoints are the ongoing Global Fund Ninth Replenishment cycle planning and UNAIDS's annual Global AIDS Update, typically released each July — both worth watching if you want a real-time read on whether 2026's crisis becomes 2027's recovery or 2027's collapse.

Florida — the domestic parallel, and where the federal thread runs through it

Florida has no direct role in PEPFAR or the Global Fund — those are foreign-assistance mechanisms, and Florida's own HIV epidemic is served through a different federal architecture, chiefly the Ryan White HIV/AIDS Program and state AIDS Drug Assistance Programs. But the connection is not merely rhetorical. The same State Department Bureau of Global Health Security and Diplomacy now responsible for PEPFAR's remaining operations sits inside the same broader shift in how the federal government thinks about global health obligations — and the domestic equivalent of "will Congress keep funding this line item at prior-year levels" is a live question for Ryan White appropriations too, not just for PEPFAR.10

Florida also has its own stake in the science moving through WHO's pipeline. The same lenacapavir that WHO recommended globally in July 2025 is the same drug the FDA approved for use in Florida clinics the previous month — meaning a Floridian on Medicaid, a Ryan White clinic, or private insurance is drawing on exactly the same trial data, the same regulatory review, and increasingly the same voluntary-licensing infrastructure that determines whether someone in a PEPFAR-supported country can access the same prevention option.14 The global and domestic HIV responses are not two separate stories. They share evidence, they share drugs, and increasingly, they share a funding climate that treats HIV programming as more discretionary than it has been treated in twenty years.